Pyrazolopyridine-based kinase inhibitors for anti-cancer targeted therapy
RSC Medicinal Chemistry · 2024 · 15 (5) · 1452-1470
DOI: 10.1039/d4md00003j ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift RSC Medicinal Chemistry, 2024. Verfasst von Pallabi Halder und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Chemistry and Chemical Biology, Indian Institute of Technology (Indian School of Mines) Dhanbad India partha@iitism.ac.in nagarajiv@iit…. Die Arbeit wurde bisher 18-mal zitiert (Crossref) und nennt 105 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: Science and Engineering Research Board, Board of Research in Nuclear Sciences.
Abstract (Originalsprache)
Pyrazolopyridines have gained increasing attention in kinase-targeting anti-cancer drug discovery. This review analyzes the success stories wherein this bicycle was employed to address various challenges.
Autor:innen und Institutionen
- Department of Chemistry and Chemical Biology, Indian Institute of Technology (Indian School of Mines) Dhanbad India partha@iitism.ac.in nagarajiv@iitism.ac.in.
ORCID-Profile: Parthasarathi Das, Naga Rajiv Lakkaniga
Förderung
- Science and Engineering Research Board
- Board of Research in Nuclear Sciences
Zitieren
APA
Halder, P., Rai, A., Talukdar, V., Das, P., & Lakkaniga, N. R. (2024). Pyrazolopyridine-based kinase inhibitors for anti-cancer targeted therapy. RSC Medicinal Chemistry, 15(5), 1452-1470. https://doi.org/10.1039/d4md00003j
Vancouver
Halder P, Rai A, Talukdar V, Das P, Lakkaniga NR. Pyrazolopyridine-based kinase inhibitors for anti-cancer targeted therapy. RSC Medicinal Chemistry. 2024;15(5):1452-1470. doi:10.1039/d4md00003j
BibTeX
@article{Halder2024,
author = {Halder, Pallabi and Rai, Anubhav and Talukdar, Vishal and Das, Parthasarathi and Lakkaniga, Naga Rajiv},
title = {Pyrazolopyridine-based kinase inhibitors for anti-cancer targeted therapy},
journal = {RSC Medicinal Chemistry},
year = {2024},
volume = {15},
number = {5},
pages = {1452--1470},
doi = {10.1039/d4md00003j}
}
EUVIMED